Future prospects in the treatment of erectile dysfunction: focus on avanafil

References

• LueTFGiulianoFMontorsiFSummary of the recommendations on sexual dysfunctions in menJ Sex Med20041162316422979
   PubMed Web of Science ®Google Scholar
• WagnerGFugl-MeyerKSFugl-MeyerARImpact of erectile dysfunction on quality of life: patient and partner perspectivesInt J Impot Res10200012Suppl 4S144S14611035403
   PubMed Web of Science ®Google Scholar
• FeldmanHAGoldsteinIHatzichristouDGKraneRJMcKinlayJBImpotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging StudyJ Urol199415154618254833
   PubMed Web of Science ®Google Scholar
• DeanRCLueTFPhysiology of penile erection and pathophysiology of erectile dysfunctionUrol Clin North Am112005324379395v16291031
   PubMed Web of Science ®Google Scholar
• LizzaEFRosenRCDefinition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence ResearchInt J Impot Res199911314114310404282
   PubMed Web of Science ®Google Scholar
• HanashKAComparative results of goal oriented therapy for erectile dysfunctionJ Urol19971576213521389146600
   PubMed Web of Science ®Google Scholar
• MontagueDKJarowJPBroderickGAChapter 1: The management of erectile dysfunction: an AUA updateJ Urol2005174123023915947645
   PubMed Web of Science ®Google Scholar
• GuptaMKovarAMeibohmBThe clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunctionJ Clin Pharmacol2005459987100316100293
   PubMed Web of Science ®Google Scholar
• NicholsDJMuirheadGJHarnessJAPharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionalityBr J Clin Pharmacol2002535S12S11879254
   PubMed Web of Science ®Google Scholar
• GingellCSultanaSRWulffMBGepi-AtteeSDuration of action of sildenafil citrate in men with erectile dysfunctionJ Sex Med20041217918416422972
   PubMed Web of Science ®Google Scholar
• CheitlinMDHutterAMJrBrindisRGUse of sildenafil (Viagra) in patients with cardiovascular diseaseCirculation19999911681779884398
   PubMed Web of Science ®Google Scholar
• BoolellMAllenMJBallardSASildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunctionInt J Impot Res19968247528858389
   PubMedGoogle Scholar
• KlotzTSachseRHeidrichAVardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic studyWorld J Urol2001191323911289568
   PubMed Web of Science ®Google Scholar
• StarkSSachseRLiedlTVardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral doseEur Urol200140218118811528196
   PubMed Web of Science ®Google Scholar
• RajagopalanPMazzuAXiaCDawkinsRSundaresanPEffect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunctionJ Clin Pharmacol200343326026712638394
   PubMed Web of Science ®Google Scholar
• GresserUGleiterCHErectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil – review of the literatureEur J Med Res200271043544612435622
   PubMed Web of Science ®Google Scholar
• EardleyICartledgeJTadalafil (Cialis) for men with erectile dysfunctionInt J Clin Pract200256430030412074215
   PubMed Web of Science ®Google Scholar
• BrockGTadalafil: a new agent for erectile dysfunctionCan J Urol.200310Suppl 1172212625846
   PubMedGoogle Scholar
• HellstromWJGOverstreetJWYuATadalafil has no detrimental effect on human spermatogenesis or reproductive hormonesJ Urol2003170388789112913723
   PubMed Web of Science ®Google Scholar
• HatzimouratidisKHatzichristouDGA comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?Drugs200565121621165016060698
   PubMed Web of Science ®Google Scholar
• VlachopoulosCIoakeimidisNRokkasKStefanadisCCardiovascular effects of phosphodiesterase type 5 inhibitorsJ Sex Med20096365867419138362
   PubMed Web of Science ®Google Scholar
• KlonerRAPharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactionsAm J Cardiol.20059612B42M46M15979430
   PubMed Web of Science ®Google Scholar
• HatzimouratidisKHatzichristouDGLooking to the future for erectile dysfunction therapiesDrugs200868223125018197727
   PubMed Web of Science ®Google Scholar
• WespesEAmarEHatzichristouDEAU guidelines on erectile dysfunction: an updateEur Urol200649580681516530932
   PubMed Web of Science ®Google Scholar
• HatzichristouDPhosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality?J Sex Med20052675175816422800
   PubMed Web of Science ®Google Scholar
• LinetOIOgrincFGEfficacy and safety of intracavernosal alprostadil in men with erectile dysfunctionN Engl J Med1996334148738778596569
   PubMed Web of Science ®Google Scholar
• KaplanSAReisRBKohnIJShabsighRTeAECombination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunctionUrology19985257397439801091
   PubMed Web of Science ®Google Scholar
• BennettAHCarpenterAJBaradaJHAn improved vasoactive drug combination for a pharmacological erection programJ Urol19911466156415651719248
   PubMed Web of Science ®Google Scholar
• MoemenMNHamedHAKamelIIShamloulRMGhanemHMClinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substancesInt J Impot Res200416214314515014552
   PubMed Web of Science ®Google Scholar
• ShokeirAAAlserafiMAMutabaganiHIntracavernosal versus intraurethral alprostadil: a prospective randomized studyBJU Int199983781281510368203
   PubMed Web of Science ®Google Scholar
• OakleyNMooreKTVacuum devices in erectile dysfunction: indications and efficacyBr J Urol19988256736819839582
   PubMedGoogle Scholar
• MinerviniARalphDJPryorJPOutcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 proceduresBJU Int200697112913316336342
   PubMed Web of Science ®Google Scholar
• MontagueDKAngermeierKWPenile prosthesis implantationUrol Clin North Am2001282355361x11402587
   PubMed Web of Science ®Google Scholar
• PaickJ-SKimSWYangDYThe efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunctionJ Sex Med20085494695318221288
   PubMed Web of Science ®Google Scholar
• PrinceWCampbellASTongWSLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjectsJ Sex Med.20063Suppl 12930
   Google Scholar
• PaickJSAhnTYChoiHKEfficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunctionJ Sex Med20085112672268018638004
   PubMed Web of Science ®Google Scholar
• HosogaiNHamadaKTomitaMFR226807: a potent and selective phosphodiesterase type 5 inhibitorEur J Pharmacol2001428229530211675048
   PubMed Web of Science ®Google Scholar
• TakagiMMochidaHNotoTPharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosumEur J Pharmacol20014111–216116811137871
   PubMed Web of Science ®Google Scholar
• HiroseROkumuraHYoshimatsuAKF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5Eur J Pharmacol20014311172411716838
   PubMed Web of Science ®Google Scholar
• QiuYBhattacharjeeSKraftPJNJ-10280205 and JNJ-10287069: novel PDE5 inhibitors as clinical candidates for erectile dysfunctionInt J Impot Res20061847748316528290
   PubMed Web of Science ®Google Scholar
• KalsiJSKellPDCellekSRalphDJNCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxideInt J Impot Res20041619520014961060
   PubMed Web of Science ®Google Scholar
• WessellsHGralnekDDorrRHrubyVJHadleyMELevineNEffect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunctionUrology200056464164611018622
   PubMed Web of Science ®Google Scholar
• MolinoffPBShadiackAMEarleDDiamondLEQuonCYPT-141: a melanocortin agonist for the treatment of sexual dysfunctionAnn N Y Acad Sci200399419610212851303
   PubMed Web of Science ®Google Scholar
• RosenRCDiamondLEEarleDCShadiackAMMolinoffPBEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to ViagraInt J Impot Res20041613514214999221
   PubMed Web of Science ®Google Scholar
• SafarinejadMRHosseiniSYSalvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled studyJ Urol200817931066107118206919
   PubMed Web of Science ®Google Scholar
• GoldsteinIPaytonTRSchechterPJA double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunctionUrology200157230130511182341
   PubMed Web of Science ®Google Scholar
• ShahPJDinsmoreWOakesRAHackettGInjection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilateCurr Med Res Opin200723102577258317875241
   PubMed Web of Science ®Google Scholar
• EardleyIWrightPMacDonaghRHoleJEdwardsAAn open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunctionBJU International20049391271127515180621
   PubMed Web of Science ®Google Scholar
• RileyAMainMMorganFInhalation device allows novel administration of apomorphine in men with erectile dysfunction – efficacy and safety findingsJ Sex Med.201074 Pt 11508151719845547
   PubMed Web of Science ®Google Scholar
• BrioniJDMorelandRBCowartMActivation of dopamine D4 receptors by ABT-724 induces penile erection in ratsProc Natl Acad Sci U S A2004101176758676315087502
   PubMed Web of Science ®Google Scholar
• SongYRajasekaranMEffect of excitatory amino acid receptor agonists on penile erection after administration into the CA3 hippocampal region in the ratUrology20046461250125415596217
   PubMed Web of Science ®Google Scholar
• AnderssonKEPharmacology of penile erectionPharmacol Rev200153341745011546836
   PubMed Web of Science ®Google Scholar
• LanceRAlboMCostabileRASteersWDOral trazodone as empirical therapy for erectile dysfunction: a retrospective reviewUrology19954611171207604472
   PubMed Web of Science ®Google Scholar
• BancilaMVergéDRampinO5-Hydroxytryptamine 2C receptors on spinal neurons controlling penile erection in the ratNeuroscience19999241523153710426504
   PubMed Web of Science ®Google Scholar
• KimuraYHatanakaKNaitouYPharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonistEur J Pharmacol20044831374314709324
   PubMed Web of Science ®Google Scholar
• KalsiJSReesRWHobbsAJBAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitroJ Urol2003169276176612544359
   PubMed Web of Science ®Google Scholar
• StaschJPBeckerEMAlonso-AlijaCNO-independent regulatory site on soluble guanylate cyclaseNature200141021221511242081
   PubMed Web of Science ®Google Scholar
• SomlyoAPSomlyoAVSignal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin IIJ Physiol2000522217718510639096
   PubMed Web of Science ®Google Scholar
• ChitaleyKWingardCJClinton WebbRAntagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathwayNat Med2001711912211135626
   PubMed Web of Science ®Google Scholar
• DaiYChitaleyKWebbRCLewisRWMillsTMTopical application of a Rho-kinase inhibitor in rats causes penile erectionInt J Impot Res20041629429814961052
   PubMed Web of Science ®Google Scholar
• SuccuSMasciaMSMelisTPro-VGF-derived peptides induce penile erection in male rats: involvement of paraventricular nitric oxideNeuropharmacology20054971017102516087201
   PubMed Web of Science ®Google Scholar
• MelisMRSuccuSSpanoMSDeghenghiRArgiolasAEP 91073 prevents EP 80661-induced penile erection: new evidence for the existence of specific EP peptide receptors mediating penile erectionNeuropharmacology20014125426211489462
   PubMed Web of Science ®Google Scholar
• MelisMRSuccuSSpanoMSEP 60761 and EP 50885, two hexarelin analogues, induce penile erection in ratsEur J Pharmacol20004041–213714310980272
   PubMed Web of Science ®Google Scholar
• MelisMRSuccuSArgiolasADopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawningEur J Neurosci1996810205620638921295
   PubMed Web of Science ®Google Scholar
• SuccuSSannaFMelisTBoiAArgiolasAMelisMRStimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: involvement of central oxytocinNeuropharmacology20075231034104317164075
   PubMed Web of Science ®Google Scholar
• MelmanABar-ChamaNMcCulloughADaviesKChristGhMaxi-K gene transfer in males with erectile dysfunction: results of the first human trialHum Gene Ther200617121165117617134370
   PubMed Web of Science ®Google Scholar
• KimEDScardinoPTHampelORIMillsNLWheelerTMNathRKInterposition of sural nerve restores function of cavernous nerves resected during radical prostatectomyJ Urol1999161118819210037395
   PubMed Web of Science ®Google Scholar
• KershenRTYooJJMorelandRBKraneRJAtalaAReconstitution of human corpus cavernosum smooth muscle in vitro and in vivoTissue Eng20028351552412167235
   PubMedGoogle Scholar
• FalkeGYooJJKwonTGMorelandRAtalaAFormation of corporal tissue architecture in vivo using human cavernosal muscle and endothelial cells seeded on collagen matricesTissue Eng20039587187914633372
   PubMedGoogle Scholar
• PilatzASchultheissDGabouevAIIsolation of primary endothelial and stromal cell cultures of the corpus cavernosum penis for basic research and tissue engineeringEur Urol200547571071915826767
   PubMed Web of Science ®Google Scholar
• LiminMJohnsenNHellstromWJGAvanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunctionExpert Opin Investig Drugs2010191114271437
   PubMed Web of Science ®Google Scholar
• PetersonCSwearingenDPharmacokinetics of avanafil, a new PDE5 inhibitor being developed for erectile dysfunctionJ Sex Med.20063Suppl 325325416490018
   PubMed Web of Science ®Google Scholar
• LewisRWHellstromWGittelmanMRigiscan evaluation of TA-1790, a novel PDE5 inhibitor for the treatment of men with erectile dysfunctionJ Urol.20061714 Suppl316
   Web of Science ®Google Scholar
• JungJChoiSChoSHTolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteersClin Ther20103261178118720637970
   PubMed Web of Science ®Google Scholar
• Results announced for TA-1790 Phase II head-to-head study with Viagra VIVUS, Inc, press releases March 4, 2004. Available from: http://www.prnewswire.com/news-releases/vivus-announces-results-for-ta-1790-in-phase-2-head-to-head-study-with-viagrar-58872542.html.
   Google Scholar
• NehraASwearingenDDietrichJPetersonCHaemodynamic effects of co-administration of avanafil and glyceryl trinitrateEur Urol.200652138
   Web of Science ®Google Scholar
• KaufmanJDietrichJSafety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction200652138
   Google Scholar
• GoldsteinI BCDiDonatoKInvestigating avanafil in the treatment of erectile dysfunction: results of a Phase III, multicenter, randomized, double-blind, placebo controlled clinical trialAUA Late-Breaking Science Forum 2010San Francisco, CA2010
   Google Scholar
• VIVUS Announces Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting. 13 September 2011. Available from: http://ir.vivus.com/releasedetail.cfm?ReleaseID=604819
   Google Scholar